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Summary
FK-506 inhibits Ca2+-dependent transcription of lymphokine genes in T cells, and thereby acts
as a powerful immunosuppressant. However, its potential therapeutic applications may be seriously
limited by several side effects, including nephrotoxicity and neurotoxicity. At present, it is unclear
whether these immunosuppressiveand toxic effects result from interference with rehted biochemical
processes. FK-506 is known to interact with FK-binding protein-12 (FKBP-12), an abundant
cytosolic protein with cis.trans peptidyl-prolyl isomerase activity (PPlase) activity. Because rapamycin
(RAP) similarly binds to FKBP-12, although it acts in a manner different from FK-506, by inhibiting
T cell responses to lymphokines, such an interaction with FKBP-12 is not suf~cient to mediate
immunosuppression. Recently, it was found that the complex of FKBP-12 with FK-506, but
not with RAP, inhibits the phosphatase activity of calcineurin. Here, we used b685,818, the
C18-hydroxy, C21-ethyl derivative of FK-506, to explore further the role of FKBP-12 in the
immunosuppressive and toxic actions of FK-506. Although b685,818 bound with high af~nity
to FKBP-12 and inhibited its PPlase activity, it did not suppress T cell activation, and, when
complexed with FKBP-12, did not affect calcineurin phosphatase activity. However, b685,818
was a potent antagonist of the immunosuppressive activity of both FK-506 and RAP. Moreover,
L-685,818 did not induce any toxicity in dogs and rats or in a mouse model of acute FK-506
nephrotoxicity, but it blocked the effect of FK-506 in this model. Therefore, FK-506 toxicity
involves the disruption of biochemical mechanisms related to those implicated in T cell activation.
Like immunosuppression, this toxicity is not due to the inhibition of the PPlase activity of FKBP-12,
but may be linked to the inhibition of the phosphatase activity of calcineurin by the drug FKBP-12
complex.

rapamycin (RAP) 1, and cyclosporin A (CsA),
define a class of immunosuppressivenatural products that
FhaveK-506,
in common the ability to inhibit T lymphocyte activation by interfering with intraceUular signaling mechanisms
(1, 2). However, these agents affect different biochemical
pathways within the cascade of events that culminate in the
expression ofT cell effector functions. Both FK-506 and CsA
disrupt T cell signaling pathways associated with a rise in
the concentration of intracellular Ca 2+ (3, 4), and this
results in the inhibition of the transcription of a family of
early activation genes, including IL-2 and IL-4 (5-7). In con1 Abbreviations used in this paper: BUN, blood urea nitrogen; CsA,
cyclosporinA; Cyp, cyclophilin;FKBP-12, FK-bindingprotein-12; PPIase,
peptidyl-prolyl isomerase activity; and RAP, rapamycin.
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trast, RAP does not inhibit Ca2+-dependent lymphokine
gene expression (5, 3), but impairs the response of T cells
to growth-promoting lymphokines (3). Furthermore, FK506 and RAP potentiate the immunosuppression induced by
CsA (8, 9), whereas, under certain conditions, they antagonize
each other's immunosuppressive action (9).
Despite thdr exquisite specificity for certain steps in T signal
transduction, these immunosuppressants have significant in
vivo toxicity. The adverse effects of FK-506 and CsA are very
similar an include neurotoxicity and nephrotoxicity (10, 11),
whereas RAP exerts little nephrotoxicity, but induces vasculitis (12) and myocardial necrosis (13). These toxic manifestations are of particular concern as they impose severe limitations in the potential therapeutic application of these
immunosuppressants. At present, it is unclear whether ira-
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munosuppression and toxicity are mediated through the alteration by the drugs of similar biochemical processes in
different cell types.
At the biochemical level, FK-506 and CsA interact with
two distinct families of intraceUular proteins, termed FKbinding proteins (FKBPs) (14) and cyclophilins (Cyps) (15),
respectively. Despite its contrasting biological activity profile,
RAP binds to the same FKBP protein family as FK-506 (16,
17). The two major forms of each of these receptor types,
FKBP-12 and Cyp A, are peptidyl-prolyl cis-trans isomerases
(PPlases), and catalyze the interconversion of the c/s and trans
rotamers of the peptidyl-prolyl amide bonds of peptide and
protein substrates (16, 18, 19). FK-506, RAP, and CsA inhibit the PPIase activity of their respective binding proteins
(16, 18-20). However, inhibition of this enzymatic activity
is not sufficient to explain the biological activities of these
immunosuppressants. We demonstrated that a CsA analog
that inhibited Cyp A PPlase activity was neither immunosuppressive nor nephrotoxic, whereas another analog, which had
little or no activity as a PPlase inhibitor, exhibited immunosuppressive activity (21). The similar potencies of FK-506 and
RAP in inhibiting the PPlase activity of FKBP-12 also suggested a dissociation between this inhibition and the mode
ofimmunosuppressive action of the macrolides (22). Moreover,
a synthetic compound (506BD), corresponding to the portion of the FK-506 molecule that binds to FKBP-12 (23),
was found to block the PPIase activity of this protein without
exerting significant immunosuppression (22).
The discovery that the molecular complexes formed between FK-506 and FKBP-12 or between CsA and Cyp A bind
to the Ca 2+- and calmodulin-dependent serine/threonine
phosphatase, calcineurin (24, 25), and inhibit its enzymatic
activity (26), may explain how these compounds exert their
immunosuppressive effects. Since a RAP:FKBP-12 complex
does not inhibit calcineurin phosphatase activity, the observations also provide an explanation for the mechanistic
similarity between FK-506 and CsA. However, because the
nonimmunosuppressive compound 506BD was found capable
of inhibiting calcineurin phosphatase activity by up to 40%
(26), additional studies with other macrolide analogs appear
necessary to establish the relevance of these in vitro effects
to immunosuppression.
In the present work, we describe b685,818, a novel nonimmunosuppressive FK-506 relative, and use this molecule as
a probe to further explore the mechanisms of action of FK506 and RAP. b685,818 is the C18-hydroxyl derivative of
L-683,590, which differs from FK-506 by a single allyl to ethyl
substitution at the C21 position of the macrolide ring (27).
We found that b685,818 binds to FKBP-12 and inhibits its
PPlase activity. However, the FKBP-12:b685,818 complex
was unable to inhibit calcineurin phosphatase activity, in contrast to the FKBP-12:b683,590 complex which was half as
active as the FKBP-12:FK-506 complex in this assay. Moreover,
L-685,818 behaved as a potent competitive antagonist of the
inhibitory effects of both FK-506 and RAP, but not of CsA,
in models of T cell activation in vitro. Although L-685,818
had no detectable toxicity in vivo, it proved to be an effective
antagonist of FK-506, but not of CsA, in a murine model
752

of drug-induced nephrotoxidty. Altogether, these studies with
L-685,818, clearly show that the inhibition of FKBP-12 PPIase
activity is not involved in either the immunosuppressive or
toxic effects of FK-506. Moreover, there exists a mechanistic
relationship between these two types of biological effects of
the drug, that may be linked to the inhibition of calcineurin
phosphatase activity.
Materials and Methods
Mice. FemaleC57B1/6 and BALB/c mice (6-12-wk-old) were
obtained from the Jackson Laboratory (Bar Harbor, ME) or from
Taconic Farms (Germantown, NY), and maintained under specific
pathogen-free conditions until use.
Reagents. FK-506and RAP were isolated by Dr. Robert Borris,
at Merck Research Laboratories (MR.L, Rahway, NJ) from Streptorayces tsukubaensis and Streptomyces hygroscopicus, respectively.
b683,590 (FK-520) was isolated from S. hygroscopicusvat. ascomycetus
by Drs. Kevin Byrne and Gino Salituro (MRL). b685,818 was synthesized by chemical modification of 1,683,590 as described elsewhere (Beattie, T., B. Arrison, and M. Wyvratt, manuscript in
preparation). Tritiated dihydro-FK-506 was provided by Dr. Allen
Jones (MRL). CsA was provided by Dr. Philippe Durette (MILL).
PMA and ionomycin were from Sigma Chemical Co. (St. Louis,
MO) and Calbiochem Corp. (LaJoUa, CA), respectively.SKF-525A
was obtained from Research Biochemicals Inc. (Natick, MA).
Recombinant human IL-lc~ was provided by Dr. Jack Schmidt
(Merck Sharp & Dohme Research Laboratories). Recombinant
human Ib2 was purchased from Amgen Biologicals (Thousand
Oaks, CA). Inhibitor I peptide (28) was obtained from Dr. Philip
Cohen (University of Dundee, UK). The routine Ib2 and IFN-3,
cDNA probes were obtained from Dr. Bill Gauss (National Institutes of Health, Bethesda, MD) and from Dr. Gordon Freeman (Dana-Farber Cancer Institute, Boston, MA), respectively.
The ~8-actin cDNA probe was obtained from Oncor Inc. (Gaithersburg, MD).
Cell Cultures. SplenicT cells from C57B1/6 mice were isolated
by nylon wool separation as previously described (3). The DO11.10 T cell hybridoma (29) was provided by Dr. Philippa Marrack
(National Jewish Center for Immunology and Respiratory Medicine, Denver, CO). The YAC-1 T cell lymphoma was obtained
from the American Type Culture Collection (Rockville, MD). Cells
were grown in culture medium made up of RPMI 1640 medium
(Gibco, Grand Island, NY) supplemented with 10% heat-inactivated
FCS, 2 mM glutamine, 1 mM sodium pyruvate, 2 • 10-5 M 2ME, and 50 #g/ml gentamycin. Microcultures of splenic T cells
were set up in flat bottomed 96-well plates (Costar Corp., Cambridge, MA). Each well received 200 gl of cell suspension at 106
cells/ml. The T cell activators and various combinations of compounds were set up in triplicate wells. The plates were incubated
at 37~ in a humidified atmosphere of 5% CO2-95% air. Cultures were pulsed with [3H]TdR (2 #Ci/well) for the last 4-5 h
of a 48-h incubation period and harvested on glass fiber filters. Incorporated radioactivity was measured by using a Betaplate liquid
scintillation spectrometer (Pharmacia-LKB, Piscataway, NJ). Cell
cultures for analysis of mKNA expression were set up in 25-cmz
tissue culture flasks (Coming Glass Works, Coming, NY) maintained in an upright position. DO-11.10 cells (2 x 10s cells/ml)
were stimulated with ionomycin plus PMA in the presence or absence of drugs, and harvested for RNA extraction after 3 h of culture. YAC-1 cells (10s cells/ml) were incubated with Ibl plus
PMA in the presence or absence of drugs, and RNA was extracted
after 20 h of culture.
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RNA Extractionand Slot Blot Analysis. Total cellular RNA was
isolated using RNAzol (Cinna/BioTeck, Friendswood, TX). RNA
samples were blotted onto nitroceUulose filters using a slot-blot
Minifold II apparatus (Bio-Rad Laboratories, Richmond, CA). The
cDNA probes were labeled with [32p]dCTP to high specific activity using a random primed DNA labeling kit (Boehringer Mannhelm, Indianapolis, IN). R.NA blots were prehybridized and
hybridized with the probes and autoradiographed using HyperfilmECL (Amersham Corp., Arlington Heights, IL).
FKBP Binding Assay. Human FKBP-12 was purified as previously described (19). An LH-20 column binding assay(15) was used
for competitive binding studies. Compounds were dissolved in ethanol and diluted in 20 mM sodium phosphate containing 0.5%
BSA (binding buffer). The reaction was set up in siliconizedroundbottomed 96-well plates. To 175 #1 of binding buffer, 25 #1 of the
competitor compound solution, 25/~1 of FKBP-12 at 250 ng/ml,
and 25/~1 of [3H]dihydro-FK-506 at 10 ng/ml, were added into
each well. After mixing and 20 min incubation at 20~ the bound
[3H]dihydro-FK-506was separated from free ligand by passing over
a 2-ml LH-20 micro-column (Pharmacia-LKB). The column was
eluted with 500/~1 of 20 mM sodium phosphate, and the void
volume counted for radioactivity. Determinations were made in
duplicate and the ICs0 calculated by linear regression on serial dilutions of competitor.
FKBP-12 PPIase Assay. The PPlase activity of FKBP-12 was
assayed as previously described (20) by measuring the c/s to trans
isomerization of the proline-phenyhhnine peptide bond in the peptide, Suc-Ala-Leu-Pro-Phe-pNA. Under equilibrium conditions,
'-88% of the peptide is present as the trans form and is readily
cleavedby chymotrypsin. The remaining 12% of the peptide present
in the c/s form is cleaved upon enzymatic conversion to the trans
form. The size of conversion was monitored by the change in absorbance at 390 nM because of the release ofp-nitroaniline. The
compounds were tested in 4-ml cuvettes containing 2.8 ml of a
70 mM solution of the substrate in assay buffer (35 mM Hepes,
pH 7.8, 3% DMSO) to which were added 30/~1 ofa 1.2-mM solution of FKBP-12. Various dilutions of compound in 10/~1 ethanol
were added, and the resulting solution was left to reach thermal
equilibrium at 10~ for 10 rain. The reaction was initiated by addition of 100 #1 of a 2.2-mM solution of chymotrypsin in 1 mM
HCI, and absorbance was recorded. The first order portion of the
resulting progress curve was fit to a simple first order rate equation. The rate constants determined from the enzymatic isomerase
activity was first corrected for the rate of nonenzymatic isomerization. This value, k~,~hb,divided by the rate constant for the reaction in the absence of inhibitor, k~.....l, was plotted as a function
of inhibitor concentration. The resulting plot was fit to a model
for tight binding inhibition to obtain K1 and [Eo].
PhosphataseAssay of Cakineurin. The assay was modified from
the procedures described by Manalan and Klee (30) and Lin et al.
(26). Inhibitor I peptide (28), which was phosphorylated with 321).
labeled ATP (450 cpm/pmol) with the catalytic subunit of cAMPdependent protein kinase, was used as a substrate. The assaybuffer
consisted of 40 mM Tris-HCl (pH 7.5), 0.1 M NaC1, 6 mM
MgC12, 0.1 mM CaC12, 0.1 mg/rrd BSA, and 0.5 mM dithiothreitol. The assay mixture (60/~1) contained 3 nM bovine brain calcineurin (Sigma), 190 nM calmodulin (Sigma), 420 nM recombinant
human FKBP-12and 7/~M ofphosphopeptide. The drug solutions
were prepared in DMSO at concentrations of DMSO <0.04% in
the final assay mixture. The incubation was carried out at 30~
for 10 min before the reaction was stopped and loaded onto 0.5-ml
Dowex AG 50W-X8 (200-800 mesh; Bio-Rad Laboratories)
columns. The level of [32p] eluted from the columns was determined by liquid scintillation radioactivity measurement.
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ToxicologicalEvaluation ofL685,818 in Dogs and Rats. Beagle
dogs (two males and two females per group) or Sprague-Dawley
rats (10 males and 10 females/group) were treated daily for 14 d
with L-685,818 or the vehicle only. L685,818 was administered by
oral gavage as a suspension in 0.5% methylcellulose, at a dose of
25 mg/kg/d. The animals were observed daily for mortality and
clinical signs of drug effect. Body weight and food consumption
were also monitored. During the secondweek of treatment, hematologic and serum biochemical examinations and urinalysis were conducted. For the dog study, plasma drug level determinations were
made on the first day of treatment and at study determination.
At necropsy, gastrointestinal tract, liver, kidneys, spleen, lymph
nodes, and thymus were examined for any gross lesions. Specimen
of these tissues were preserved in 10% neutral buffered formalin
and examined microscopicallyusing paraffin-embedded and hematoxylin/eosin-stained sections.
Murine Acute Nephrotoxicity Assay. Treatment with the cytochrome P450 inhibitor, SKF-525A (31), was used to enhance the
toxicity of FK-506 in BALB/c mice (Koprak, S., and F. Dumont,
manuscript in preparation). SKF-525A was dissolved in saline, and
a dose of 75 mg/kg was injected intraperitoneally 2 h before intravenous injection of 0.5 ml of the compound or vehicle control solutions. Stock solutions of compounds were made up in ethanol
at 65 rag/m1, further diluted in ethanol, and mixed with
Cremophor| (BASF, Parsippany, NJ) followed by saline, to give
final solutions containing 10% (wt/vol) Cremophor| and 6% ethanol. The vehicle control solution was made up of saline with the
same concentrations of Cremophor| and ethanol. The mice received these injections for 2 consecutive d and were killed the following day for autopsy and collection of serum and tissue (kidney,
liver) samples. Measurement of blood urea nitrogen (BUN) levels
in the serum was done on an autoanalyzer (model 203; Gilford
Instrument Laboratories, Inc., Oberlin, OH).
Results
L.685,818 Binds to FKBP-12 and Inhibits its PPIase Activity
but Does Not Inhibit T Cell Activation. As shown in Fig. 1,
the chemical structure of b685,818 is closdy related to that
of FK-506. L-685,818 was synthesized from I.-683,590, which
differs from FK-506 by an ally1 to ethyl substitution at the
C21 position (27). b685,818 also contains a hydroxyl group
at the C18 position of the macrolide ring. Consistent with
their structural similarity to FK-506, both L-685,818 and
I--683,590 bind to FKBP-12 with a high af~nity (Fig. 2 a).
Furthermore, L-685,818 is a potent inhibitor of the PPlase
activity of this protein, comparable with FK-506 or RAP
(Fig. 2 b).
In contrast to its activity in these biochemical assays,
1.-685,818 did not inhibit the proliferation of T cells activated
by ionomycin plus PMA, even when tested at concentrations
up to five orders of magnitude >FK-506 (Fig. 2 c). Under
the same conditions, L-683,590 was only threefold less potent than FK-506, in agreement with earlier studies (27).
I--685,818, at concentrations as high as 25/~M, also had little
effect on IL-2 plus PMA-induced T cell proliferation, whereas,
as previously reported (3), such a response was suppressed
by subnanomolar concentrations of RAP (Fig. 2 d).
The Complex FKBP12:L685,818 Does Not Inhibit Cakineurin
Phosphatase Activity. It was reported recently that the molecular complex formed between FKBP-12 and FK-506 is able
to inhibit the Ca2+/calmodnlin-dependent phosphatase ac-
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Figure 1. Comparison of the chemical
structuresof I~-506,1,683,590 (FK-520),and
1,685,818. Note the C21 ethylsubstitutionin
I~683,590 (*) and the C18 hydr~yl substitution in 1,685,818 (**).

ious concentrations of L-685,818 were added simultaneously.
As shown in Fig. 4 a, concentrations of L-685,818 >100 nM
completely reversed the suppressive effect of FK-506. Therefore, 1,685,818 is a potent antagonist of FK-506 (EDs0 -63.1 _+ 7.2 ruM, mean _+ SEM of 13 experiments). In contrast, L-685,818 failed to reverse the inhibitory effect of CsA
in T cell cultures similarly stimulated with ionomycin plus
PMA (Table 1).
The Schild analysis method is used to determine the affinity
of a pharmacological antagonist in a biological system (32),
and was employed here to further evaluate the antagonist activity of L-685,818. T cells stimulated with ionomycin plus
PMA were cultured in the presence of vafious concentrations
of FK-506 either alone or together with increasing concentrations of L-685,818. Fig. 4 b demonstrates that addition of
1,685,818 concentrations ranging from 19 nM to 2.5/~M progressively shifted the dose-response inhibition curve of FK506 to the fight, indicating a decreased sensitivity of the ceils
to the immunosuppressant. Calculation of the EDs0s of the
inhibitory effect of FK-506 in the absence or presence of vat-
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tivity of calcineurin in vitro (26). We wished to address the
possibility that the lack of biological activity of L-685,818
was due to its inability to inhibit calcineurin phosphatase in
the presence of FKBP-12. As shown in Fig. 3, when tested
under experimental conditions where FK-506 and L-683,590
could block caldneurin function with EDs0s of 57 and 108
riM, respectively, L-685,818 was totally inactive at concentrations up to 2 #M. Consistent with the data of Liu et al.
(26), RAP also failed to suppress the phosphatase activity
of caldneurin, even at concentrations 40-fold higher than
FK-506.
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Figure 2. 1,685,818(A) binds to FKBP-12(a) and inhibits
its PHase activity(b), but does not inhibit the proliferative
responses of T ceils stimulated,either with ionomycinplus
PMA (c), a mode of activationsensitiveto FK-506(O) and
1,683,590 (A), or with I1,2 phs PMA (d), a modeof activation sensitiveto RAP (r-I). The bindingto FKBP-12was determined in a competitiveassayusing [3H]dihydro-FK-506.
The EDsosfor each compoundare indicatedon the figure.
The inhibitionof PPlaseactivityof FKBP-12was verysimilar
for the three compoundsexamined.The line correspondsto
the bestfit calculatedby a nonlinearregressionanalysis,Mouse
splenic T cells were cultured with ionomycin(250 ng/ml)
plus PMA (10 ng/ml) or with IL-2(100 U/ml) plus PMA
(10 ng/ml)in the presenceof variousconcentrationsof compounds, and the cell proliferationwas measuredby [3H]TdR.
uptakeafter2 d of culture. The resultswereexpressedas percent of the control [3H]TdRincorporationin cultures that
receivedthe stimulionly (ionomycin- PMA - 467 x 103
cpm, I1,2 + PMA = 550 x 103 cpm).
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ious concentrations of L-685,818 allowed us to characterize
the interaction of the two macrolides with their common
receptor. The data plotted in Fig. 4 c indicate that L685,818
competes with FK-506 for a single functional receptor in T
cells (32). As calculated by this method, the Ka of the interaction of L-685,818 with this putative receptor is 8.7 +
1.0 nM (mean _+ SEM of four experiments).
We next examined whether L-685,818 would reverse the
immunosuppressive effect of RAP in T cells stimulated with
ID2 plus PMA. Using RAP at a concentration of 1.1 nM,
which inhibited the proliferative response by 70-75%, the
addition of 1.-685,818 resulted in a dose-dependent restoration of the proliferative response, with an EDs0 -- 45.5 +
6.0 nM (mean • SEM of six experiments), as shown in Fig.
4 d. Schild analysis (Fig. 4, e and J) further demonstrated
that L-685,818 acts as a competitive antagonist of RAP at
the level of a single functional site with a Ka of 4.4 • 0.5
nM (mean • SEM of three experiments). This value is close,
but not identical to the Ka determined for FK-506 competition (Student's t test, p = 0.03).

1_,685,818 Reverses the ImmunosuppressiveE~ects of FK-506
or RAP Even When Added Late into the Cultures. Experiments
were then conducted to define the temporal site of this antagonistic effect of L685,818. Fig. 5 a demonstrates that, when
added as late as 6 h after FK-506 in T cell cultures activated
with ionomycin plus PMA, b685,818 still fully restored the
proliferative response measured at 48 h of culture. L-685,818
also reversed the inhibition of PAP by more than 50% even
when added up to 12 h after the latter to cuhures stimulated
with Ib2 plus PMA (Fig. 5 b). Therefore, L-685,818 competes at the level of the functional receptors that mediate the
pharmacologic action of the immunosuppressants, rather than
at the level of a transport mechanism necessary for entry of
the macrolides into the cell.

1-,685,818 Antagonizes the SuppressiveEffects of FK-506 and
RAP on Lymphokine mRNA Induction. To confirm that
1-685,818 acted as an antagonist at the level of transcriptional
regulation, we studied its effect on IL2 mKNA induction
in DO-11.10 hybridoma T cells activated with ionomycin plus
755
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Figure 4. L-685,818antagonizes the immunosuppressive effects of FK506 (a-c) and RAP (d-J~ in activated T cells. (a) Mouse splenic T cells
were activated with ionomycin plus PMA in presence of 1.2 nM FK-506,
and various concentrations of b685,818 were added at the initiation of
the cultures. (b) Mouse splenic T cells were activated with ionomycinplus
PMA in presence of various concentrations of FK-506 either alone
(O - - O) or with b685,818 at concentrations increasing in twofold increments from 19 nM to 2.5/~M. (c) Schild analysis of the antagonism of
FK-506 by b685,818 in the experiment depicted in (b). (d) Mouse splenic
T cells were activated with IL-2 plus PMA in presence of 1.1 nM RAP,
and various concentrations of b685,818 were added at the initiation of
the cultures. (e) Mouse splenic T cells were activated with II=2 plus PMA
in presence of various concentrations of RAP, either alone (O-O) or with
L-685,818 at concentrations increasing in twofold increments from 19 nM
to 2.5/~M. (f) Schild analysis of the antagonism of RAP by L-685,818
in the experiment depicted in (e).

PMA. Fig. 6 a shows that Ib2 mRNA was detectable 3 h
after activation and was inhibited by FK-506 in a dosedependent manner. L685,818 had no effect on this induction
of ID2 mRNA expression, but it blocked the inhibitory effect
of FK-506. In a different modal of lymphokine gene regulation, the induction of IFN-'y mRNA by IL-1 plus PMA in
the YAC-1 T cell lymphoma (33), PAP was inhibitory at
concentrations as low as 1 nM (Fig. 6 b). b685,818, tested
at 12/~M, did not inhibit IFN-3, mRNA expression and totally restored this expression in PAP-treated cultures.
1..685,818Is Not Toxicin DogsandRats. Basedon the afor~
mentioned data, b685,818 appeared as an excellent tool to
address the question of the mechanistic relationship between
F~-506 immunosuppression and toxicity. First, we investigated

Table 1. L-685,818 Does Not Block the Suppressive Effect of CsA in T Cells Stimulated with Ionomycin Plus PMA *
T call proliferation ([3H]TdR uptake)t
No L-685,818
CsA concentration

+ L-685,818 (25/~M)

cpm x 10 -35

Percent control II

cpm x 10 -3

0

341.0

100.0

332.6

100.0

6

355.8

104.3

395.3

118.9

12

340.2

99.8

377.1

113.4

25

355.6

104.3

268.8

80.8

50

161.9

47.5

56.0

16.8

100

65.1

19.1

21.2

6.4

200

32.2

9.4

18.8

5.7

Percent control

nM

" Mouse splenic T cells were stimulated for 48 h with ionomycin (250 ng/ml) plus PMA (10 ng/ml).
* Cell proliferation was measured by pulsing the cultures with 2/xCi[3H]TdR for 4 h.
S Each value is the mean of triplicate wells.
UControl proliferative response of cells stimulated wth ionomycin plus PMA in the absence of drug.

whether I.,685,818 would exert any of the side effects previously noted with FK-506 in animal models (10). Although
highly sensitive to the toxic effects of FK-506 (34) or RAP
(12), dogs were unaffected by a 2-wk oral treatment with
a

Iono + PMA, FK-506 1.2 nM

150-

7550-

~- 2s

8
"~100~

50
25
0

No 0
1
3
6
9 12 25 36
818 L---+ 818 (Time of Addition, Hours)~

Figure 5. L-685,818 reverses the suppression of T cell proliferative responses by FK-506 (a) or RAP (b) even when added after either immunosul>
pressant to the cultures. (a) Mouse splenic T cells were activated with
ionomycin plus PMA, and FK-506 (1.2 riM) was added at the initiation
of the cultures. Replicate wells received L-685,818 (125 nM) either at the
same time as FK-506 (t = 0) or at various times thereafter. (b) Mouse
splenic T cells were activated with IL-2 plus PMA and RAP (1.1 riM) was
added at the initiation of the cultures. Replicate wells received L-685,818
(125 riM) either at the same time as RAP (t = 0) or at various times
thereafter. In both (a) and (b), the cultures were harvested after 48 h of
incubation after a 6-h pulse with [3H]TdR.. The results were expressed
as percent of the control response obtained with ceils stimulated in the
absence of compound (ionomycin + PMA = 425 x 103 clan, IL-2 +
PMA = 623 x 103cpm).
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L-685,818 at doses as high as 25 mg/kg/d, which gave plasma
drug levels >2 /xg/ml. Similarly, oral administration of
D685,818 in rats for 2 wk at 25 mg/kg/d, failed to cause
the nephrotoxicity or behavioral changes that have been observed with FK-506 (10, 11). Therefore, b685,818 is devoid
of the toxicity known to be associated with FK-506.
L685,818 Blocks the Nephrotoxic Action of FK-506. To examine the possibility that L-685,818 could antagonize FK506-induced toxicity, we used an acute model in BALB/c mice,
where the nephrotoxic potential of FK-506 was enhanced by
cotreatment of the animals with the inhibitor of cytochrome
P450, SKF-525A (31). Consistent with the recently demonstrated role of P450 enzymes in the metabolism of FK-506
(35), we found that SKF-525A augmented the serum level
of FK-506 (not shown). Under these conditions, two daily
intravenous injections of FK-506 in doses ranging from 3.1
to 12.5 mg/kg were sufficient to induce a significant elevation of BUN levels. I.-683,590 (50 mg/kg) was also found
to raise BUN concentration, whereas RAP (100 mg/kg) had
no effect on this parameter, although it caused mortality (Table
2). In contrast, the same protocol of treatment with 100
mg/kg of b685,818 did not produce any increase of BUN
or mortality (Table 2 and Fig. 7). It is most interesting that
administration of this high dose of b685,818, together with
toxic doses of FK-506, prevented almost completely the rise
in BUN observed with FK-506 alone (Fig. 7 a). The dosedependent nature of the antagonism is demonstrated in Fig.
7 b, where the animals were given a constant dose of FK-506
and varying doses of I~685,818. Therefore, L-685,818 is a potent antagonist of the acute nephrotoxic effect of FK-506 in
this murine model Additional experiments (not shown)
demonstrated that b685,818 does not block CsA-mediated
nephrotoxicity.

Immunosuppression and Toxicity by FK-506 are Mechanistically Related

T a b l e 2. Effects of Two Daily Intravenous Injections of FK-506,
L-683,590, RAP, or L-685,818 on BUN Levels in BALB/c
Mice Cotreated with SKF-525A *
Treatment
(Dose, mg/kg)

Expt. no.
1

2

3

Figure 6. L-685,818blocks the inhibitoryeffects ofFK-506 (a) and RAP
(b) on lymphokine mRNA induction. (a) DO-11.10 cells were activated
with ionomycin plus PMA in presence or absence of various concentrations of FK-506, without or with L-685,818 (12 #M). The cells were harvested after 3 h of culture, and total RNA was extracted and blotted onto
a nitrocellulose filter. The blot was hybridized'with the Ib2 cDNA probe,
stripped, and rehybridized with the actin cDNA probe. (b) YAC-1 cells
were activated with IL-1 plus PMA in presence or absence of various concentrations of RAP, without or with b685,818 (12 ~tM). The cells were
harvested after 20 h of culture and total RNA was extracted and blotted
onto a nitrocellulose filter. The blot was hybridized with the IFN-T cDNA
probe, stripped, and rehybridized with the actin cDNA probe.

Discussion

The present study exploits the unique pharmacological
properties of b685,818 to investigate the mechanism of action of FK-506 with respect to its biochemical target for immunosuppression, and the relationship between this target
and toxicity, b685,818 differs from FK-506 at two positions.
Although the aUyl to ethyl substitution at the C21 position
results in a two to threefold loss in immunosuppressive potency,
it is the addition of a hydroxyl group at the C18 position
of the macrolide ring that converts the molecule to an antagonist. Recent x-ray crystallographic and nuclear magnetic
resonance studies indicate that I.-685,818 associates with
FKBP-12 through its pipecolic acid portion, in a manner identical to FK-506 (Becker, J., manuscript in preparation). Hence,
it is not surprising that FK-506 and L-685,818 have equivalent activities in binding to FKBP-12 and in inhibiting its
PPlase activity, since it is their common "face" that is responsible for these activities. Such observations are consistent with
earlier studies using 506BD and RAP (22).
The observation that the physical interaction with FKBP-12
and the inhibition of PPIase may be necessary but not sufficient
for immunosuppression has led to the hypothesis that the
drugs must interact with other cellular components to disrupt the signaling processes of T cell activation (1, 2). This
hypothesis is supported by the recent finding that the corn757
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BUN (mg/dl)
Mean (SEM)

Vehicle

14.4 (0.5)

FK-506 (12.5)
L-683,590 (50)

61.0 (16.2)
50.2 (11.4)

Vehicle

20.7 (1.3)

FK-506 (12.5)
RAP (100)

p*

Mortality
0/6

0.007
0.007

2/6
1/6

34.8 (1.7)
22.2 (1.7)

0.0001
0.5

0/6
3/8

Vehicle
FK-506 (12.5)

14.7 (0.9)
85.8 (15.6)

0.0007

0/6
1/6

L-685,818 (100)

16.2 (0.7)

0.2

0/6

0/6

* Mice received an intraperitoneal injection of SKF-525A (75 mg/kg)
2 h before intravenous administration of the compounds. The animals
were treated for 2 consecutive d and killed the next day.
t Statistical significance determined by Student's t test.

plex formed between FKo506 and FKBP-12 interacts with
the CaZ+-calmodulin-dependent phosphatase, calcineurin,
and inhibits its phosphatase activity in vitro (26). We found
here that I.-685,818 is unable to alter the activity of calcineurin
in such a system, even when tested at concentrations up to
40-fold greater than FK-506, whereas b683,590 did inhibit
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Figure 7. L-685,818 does not increase BUN but blocks the BUN
elevating effect of FK-506 in BALB/c mice cotreated with SKF-525A. The
mice received SKF-525A (75 mg/kg) intraperitoneaUy 2 h before intravenous injection of FK-506 or 1--685,818 either alone or in combination.
Control (Ct) mice received SKF-525A and the vehicle alone. All mice were
treated on 2 consecutive d and were bled and killed the following day.
(a) I.-685,818 was administered at 100 mg/kg/d ([]). FK-506 was given
at 1.6, 3.1, or 6.2 mg/kg/d either alone (g3) or together with I--685,818
(100 mg/kg/d, m). The results are the pooled data from three experiments, with each group including a total of 15-18 mice. (b) FK-506 was
given at 6.2 mg/kg/d either alone ([]) or together with various doses
of I.,685,818 ( I ) . The results are the pooled data from two experiments,
with each group includinga total of 9-12 mice. The statistical significances
(Student's t test) of the differences in BUN'between the groups treated
with FK-506 alone and the control group, and between the groups treated
with FK-506 alone or with 1.,685,818are indicated ( * ) p <0.1, ( * * ) p <0.01.

this activity with a potency approximatdy twofold lower than
FK-506. This demonstrates a clear-cut corrdation between
the ability of the drugs complexed to FKBP-12 to interfere
with the phosphatase activity of calcineurin and their ability
to suppress T cell activation induced in a Ca2+-dependent
manner. Such a correlation suggests that the inhibition of
caldneurin enzymatic function by the FKBP-drug complex
may be involved in the mechanism of immunosuppressive action of the drugs. Although a similar conclusion had been
made based on studies with RAP (26), the strict concordance
between the biochemical and cellular observations produced
by a subtle structural change, such as the 18-hydroxy substitution, further solidifies this model.
Are the molecular entities defined in the current in vitro
caldneurin assay system the relevant members of the complex that mediate immunosuppressive activity in vivo? There
are severalreasons to consider this question. First, the in vitro
system used in both the present and previous (26) studies
is based on the interaction of heterologous proteins (bovine
calcineurin and calmodulin with human FKBP-12). Second,
the existence of severalisoenzymes of calcineurin (25) should
be noted. Third, a number of minor forms of FKBPs have
now been identified in mammalian cells (36-38).
Recent genetic experiments strongly implicate calcineurin
as a component of a drug-sensitivesignal transduction pathway
in T cells. O'Keefe, et al. (38a) have demonstrated that transfection of a mutant, constitutively active, catalytic subunit
of calcineurin into Jurkat cells synergizes with PMA alone
to activate the II~2 promoter in an FK-506- and CsA-sensitive
manner. Although similar experiments have not been performed with FKBP-12, several results have called into question the assumption that the most abundant immunosuppressant receptors must mediate all the biological effects of
FK-605 and CsA. In yeast, deletion of FKBP-12 does not
confer resistance to the growth inhibitory effects of FK-506
(39), suggesting the existenceof other FKBP family members.
Pharmacologicalexperiments with CsA analogs also suggested
that Cyp A may not be the member of this family to mediate
the immunosuppressive activity of CsA (21). Thus, whereas
genetic studies dearly put calcineurin in the drug-sensitive
signal transduction pathway, experiments performed to date
do not permit us to identify which FKBP family member
is the most relevant effector of calcineurin complex formation in vivo.
The identification ofb685,818 as the most potent antagonist
of both FK-506 and RAP-mediated immunosuppression synthesized to date has allowed us to explore the nature of the
functional receptor of these compounds from a different perspective. Sehild ~n~lysiswas used to demonstrate that b685,818
interacted with a single receptor species when either FK-506
or RAP was used as the agonist. Furthermore, since b685,818
could be added to the cultures several hours after FK-506,
and since FK-506 is known to penetrate and reach equilibrium within the cells in <20 rain (14), we concluded that
the antagonism of b685,818 does not reflect inhibition of
a transport mechanism. The most straightforward conclusion from these data is that b685,818 antagonizes FK-506
and RAP through their interaction with a common cellular
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receptor, a notion already suggested by the fact that the two
drugs antagonize each other's action with similar potencies
(9). More through analysis suggests alternative possibilities,
however. The affinities derived by Schild analysis (4-8 riM)
differ significantly from those estimated from FKBP-12 competitive binding measurements (0.7 riM). This diffgrencemay
be due to relative abundance of the relevant drug receptor
within the cell. However, given the fact that the intracellular
concentration of FKBP-12 is '~5-10/~M (Dumont, F. et al.,
manuscript in preparation), one might expect that even larger
concentrations of I.-685,818 would be required to observe antagonism and that the antagonism might be noncompetitive. Taken together, Ka estimates derived from the Sehild
analysis are not entirely consistent with the assumption that
the antagonist and agonists are distributed uniformly within
the FKBP-12 cytosolicreceptor pool. Indeed, FK-506 and RAP
may interact with receptors that are in lower abundance than
FKBP-12, or may bind preferentially to a distinct subset
of FKBP-12 molecules within the cell. Therefore, although
FKBP-12 appears as the most plausible intracellular target
for these compounds, we cannot exclude the possibility that
another known, or as yet undiscoveredFKBP may be involved.
The present study provides important insights into the relationship between the immunosuppressive and toxic effects
of FK-506. Along with its lack of immunosuppressive activity, I.-685,818 did not elicit any of the side effects known
to occur after FK-506 treatment in several animal species, including the gastrointestinal pathology seen in dogs (34) and
the nephrotoxicity observed in rats (11). Using a mouse model
where the nephrotoxic effectof FK-506 was enhanced by coadministration of the I}450 inhibitor SKF-525A (31), we found
that L-685,818 produced little or no elevation of BUN, even
when given at doses 5-10-fold greater than nephrotoxic doses
of FK-506. Since interfering with FK-506 metabolism potentiates the toxicity of the drug, it is likely that the parent compound, rather than metabolites, may be primarily responsible
for the induction of nephrotoxicity. Furthermore, the use of
an inhibitor of macrolide metabolism also minimizes the possibility that b685,818 could be modified in vivo. The most
striking observation made with this modal, however, is that
b685,818 reversedthe nephrotoxic action of FK-506 in a dosedependent manner.
The finding that the toxic effects of FK-506 can be reversed
by the same antagonist that blocks FK-506 immunosuppression strongly suggests that the mechanisms of immunosuppression and toxicity are related. FK-506 may therefore affect
biochemical processes that are part of signal transduction
pathways shared in common by lymphoid calls and by nonlymphoid calls in the target toxicity organs. As for immunosuppression, it is unlikely that these processes involve
inhibition of PPlase activity, which is similar to the conclusion reached in an analysis of CsA analogs (21). Instead, the
toxicity of FK-506 may be linked to the ability of the drugFKBP-12 complex to inhibit the phosphatase activity of calcineurin. This conclusion may also explain why FK-506 and
CsA share such similar patterns of toxicity (11).
Since FKBPs, Cyps, and calcineurins are widely distributed,
it may be surprising that FK-506 and CsA do not produce
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even more toxicity. There may be several reasons for the apparent sdectivity of the drugs. Although calcineurin is present
in a variety of tissues, it differs in abundance and isoenzyme
distribution pattern (25), and may have diverse roles in the
physiology of the cells. The substrates for calcineurin may
also differ among cells. In addition, selectivity could be related
to the tissue distribution of related FKBPs that would confer

the appropriate aff~ty and fimctional ability of the drug complex to interfere with calcineurin. Nevertheless, the finding
that immunosuppression and toxicity of FK-506 are mechanistically related will make it difficult to dissociate the immunosuppressive activity and toxic effects of molecules that
use such common biochemical pathways.
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